JP2025504363A5 - - Google Patents

Info

Publication number
JP2025504363A5
JP2025504363A5 JP2024540715A JP2024540715A JP2025504363A5 JP 2025504363 A5 JP2025504363 A5 JP 2025504363A5 JP 2024540715 A JP2024540715 A JP 2024540715A JP 2024540715 A JP2024540715 A JP 2024540715A JP 2025504363 A5 JP2025504363 A5 JP 2025504363A5
Authority
JP
Japan
Prior art keywords
seq
cancer
amino acid
acid sequence
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024540715A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504363A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/060074 external-priority patent/WO2023133394A1/en
Publication of JP2025504363A publication Critical patent/JP2025504363A/ja
Publication of JP2025504363A5 publication Critical patent/JP2025504363A5/ja
Pending legal-status Critical Current

Links

JP2024540715A 2022-01-05 2023-01-04 γδT細胞結合ポリペプチド及びその使用 Pending JP2025504363A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263296774P 2022-01-05 2022-01-05
US63/296,774 2022-01-05
US202263417926P 2022-10-20 2022-10-20
US63/417,926 2022-10-20
PCT/US2023/060074 WO2023133394A1 (en) 2022-01-05 2023-01-04 Gamma delta t-cell-binding polypeptides and uses thereof

Publications (2)

Publication Number Publication Date
JP2025504363A JP2025504363A (ja) 2025-02-12
JP2025504363A5 true JP2025504363A5 (cg-RX-API-DMAC7.html) 2025-12-26

Family

ID=85199216

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024540715A Pending JP2025504363A (ja) 2022-01-05 2023-01-04 γδT細胞結合ポリペプチド及びその使用

Country Status (11)

Country Link
US (1) US20250066477A1 (cg-RX-API-DMAC7.html)
EP (1) EP4460521A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025504363A (cg-RX-API-DMAC7.html)
KR (1) KR20240130130A (cg-RX-API-DMAC7.html)
CN (1) CN119213028A (cg-RX-API-DMAC7.html)
AU (1) AU2023205911A1 (cg-RX-API-DMAC7.html)
CA (1) CA3242658A1 (cg-RX-API-DMAC7.html)
IL (1) IL314073A (cg-RX-API-DMAC7.html)
MX (1) MX2024008389A (cg-RX-API-DMAC7.html)
TW (1) TW202334233A (cg-RX-API-DMAC7.html)
WO (1) WO2023133394A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025140683A1 (zh) * 2023-12-29 2025-07-03 北京鼎成肽源生物技术有限公司 表达趋化因子10和白介素15的工程化免疫细胞
WO2025144974A1 (en) * 2023-12-29 2025-07-03 Absci Corporation Half-life extending fc domain variants and uses thereof
WO2026006719A1 (en) * 2024-06-28 2026-01-02 IN8bio, Inc. Multifunctional molecules and methods of treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DK1678314T3 (da) 2003-10-22 2012-12-03 Keck Graduate Inst Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US10501540B2 (en) * 2014-04-10 2019-12-10 Lava Therapeutics B.V. Immunoglobulins binding human Vγ9 Vδ2 T cell receptors
GB201707048D0 (en) * 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
JP7611820B2 (ja) * 2018-10-11 2025-01-10 インヒブルクス バイオサイエンシズ インコーポレイテッド Dll3シングルドメイン抗体およびその治療用組成物
WO2020159368A1 (en) * 2019-02-01 2020-08-06 Lava Therapeutics B.V. Novel cd40-binding antibodies
KR20220004751A (ko) * 2019-05-04 2022-01-11 인히브릭스, 인크. CLEC12a 결합 폴리펩타이드 및 이의 용도
IL293459A (en) * 2019-12-03 2022-07-01 Adicet Bio Inc Methods for expanding γδ t-cell populations with multivalent agents and compositions thereof
CR20220431A (es) * 2020-03-03 2023-02-21 Janssen Biotech Inc CÉLULAS T yo Y USOS DE ESTAS

Similar Documents

Publication Publication Date Title
JP2023513003A5 (cg-RX-API-DMAC7.html)
JP2024526835A5 (cg-RX-API-DMAC7.html)
JP2020536549A5 (cg-RX-API-DMAC7.html)
JP2020516287A5 (cg-RX-API-DMAC7.html)
JP2021520812A5 (cg-RX-API-DMAC7.html)
JP2022516557A5 (cg-RX-API-DMAC7.html)
Nie et al. Biology drives the discovery of bispecific antibodies as innovative therapeutics
JP2019513347A5 (cg-RX-API-DMAC7.html)
TWI828625B (zh) 引導及導航控制蛋白質以及彼之製造及使用方法
RU2020142965A (ru) Иммуноглобулин с тандемным расположением fab-фрагментов и его применение
RU2018106452A (ru) Поливалетные и полиспецифичные gitr-связывающие слитые белки
IL312224B1 (en) Guidance and navigation control proteins and method of making and using thereof
JP2017513818A5 (cg-RX-API-DMAC7.html)
RU2018128462A (ru) Модифицированные клетки для иммунотерапии
CN104592392B (zh) 一种双特异性抗体EpCAM×CD3的构建及应用
JP2017506513A5 (cg-RX-API-DMAC7.html)
JP2017506215A5 (cg-RX-API-DMAC7.html)
JP2015527070A5 (cg-RX-API-DMAC7.html)
FI3611192T3 (fi) Tcr alfa/beeta-reaktiivisuuteen perustuvia, t-soluja rekrytoivia polypeptidejä
JP2017507917A (ja) 軟骨魚類由来の抗原認識ドメインを使用したキメラ抗原受容体
HRP20190756T1 (hr) Cd3-vezujuće molekule sposobne za vezanje za humani i nehumani cd3
CN108250302A (zh) 一种多功能蛋白质
JP2021534784A5 (cg-RX-API-DMAC7.html)
JP2024534471A5 (cg-RX-API-DMAC7.html)
JP2024546999A5 (cg-RX-API-DMAC7.html)